Tumor enlargement in adrenal incidentaloma is related to glaucoma: a new prognostic feature?
Adrenal
Enlargement
Glaucoma
Incidentaloma
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
12
01
2023
accepted:
05
07
2023
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
aheadofprint
Résumé
The uncertainty on the management of small adrenal incidentalomas (AIs) still represents a challenge in real clinical practice. Considering the lack of knowledge on risk factors implicated in tumour enlargement, the aim of this study was to identify risk factors for morphological changes during follow-up of adrenal incidentalomas (AIs). We retrospectively evaluated demographic, clinical, radiological and biochemical parameters of 153 AIs (2007-2021). Patients with histological diagnosis of metastases or pheochromocytoma were excluded. To detect risk factors for tumor enlargement, diseases associated with AIs were included if their prevalence was higher than 2%. Patients were divided into two groups (A: radiological stability; B: tumor enlargement defined as > 5 mm/year in the main diameter). Group A: 89.5% and group B: 10.5%, mean follow-up 38.6 ± 6.9 months (range 6-240). Tumor enlargement when occurred was within 36 months of follow-up. In group B high body weight (p < 0.03), dehydroepiandrosterone sulfate (DHEAS) (p < 0.05) and direct renin concentration (DRC) (p < 0.04) were higher than group A, while aldosterone levels were lower; moreover, considering comorbidities, glaucoma and dysglycemia (p < 0.01 for both) had higher prevalence in group B. Glaucoma and dysglycemia were independent predictors of enlargement. Patients affected by glaucoma, atrial fibrillation, dysglycemia had a lower dimensional change-free survival than non-affected. Glaucoma might be a novel risk factor for AI enlargement. If subtle undetectable cortisol hypersecretion has a role is a topic for further research.
Identifiants
pubmed: 37466811
doi: 10.1007/s40618-023-02154-9
pii: 10.1007/s40618-023-02154-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, Angeli A, Terzolo M (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29(4):298–302. https://doi.org/10.1007/BF03344099
doi: 10.1007/BF03344099
pubmed: 16699294
Reimondo G, Muller A, Ingargiola E, Puglisi S, Terzolo M (2020) Is follow-up of adrenal incidentalomas always mandatory? Endocrinol Metab (Seoul) 35(1):26–35. https://doi.org/10.3803/EnM.2020.35.1.26
doi: 10.3803/EnM.2020.35.1.26
pubmed: 32207261
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 175(2):G1–G34. https://doi.org/10.1530/EJE-16-0467
doi: 10.1530/EJE-16-0467
pubmed: 27390021
Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, Giovagnetti M, Opocher G, Angeli A (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85(2):637–44. https://doi.org/10.1210/jcem.85.2.6372
doi: 10.1210/jcem.85.2.6372
pubmed: 10690869
Menegaux F, Chéreau N, Peix JL, Christou N, Lifante JC, Paladino NC, Sebag F, Ghander C, Trésallet C, Mathonnet M (2014) Management of adrenal incidentaloma. J Visc Surg 151(5):355–364. https://doi.org/10.1016/j.jviscsurg.2014.07.002
doi: 10.1016/j.jviscsurg.2014.07.002
pubmed: 25127879
Hong AR, Kim JH, Park KS, Kim KY, Lee JH, Kong SH, Lee SY, Shin CS, Kim SW, Kim SY (2017) Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Eur J Endocrinol 177:475–483. https://doi.org/10.1530/EJE-17-0372
doi: 10.1530/EJE-17-0372
pubmed: 28870984
Bancos I, Prete A (2021) Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab 106(11):3331–3353. https://doi.org/10.1210/clinem/dgab512
doi: 10.1210/clinem/dgab512
pubmed: 34260734
pmcid: 8530736
Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M (1999) Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84(2):520–526. https://doi.org/10.1210/jcem.84.2.5444
doi: 10.1210/jcem.84.2.5444
pubmed: 10022410
Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S, Salcuni AS, Dolci A, Mendola M, Arosio M, Ambrosi B, Scillitani A, Ghigo E, Beck-Peccoz P, Terzolo M, Chiodini I (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99(3):827–834. https://doi.org/10.1210/jc.2013-3527
doi: 10.1210/jc.2013-3527
pubmed: 24423350
Singh S, Atkinson EJ, Achenbach SJ, LeBrasseur N, Bancos I (2020) Frailty in patients with mild autonomous cortisol secretion is higher than in patients with nonfunctioning adrenal tumors. J Clin Endocrinol Metab 105(9):e3307–e3315. https://doi.org/10.1210/clinem/dgaa410
doi: 10.1210/clinem/dgaa410
pubmed: 32628749
pmcid: 7382051
Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, Mosconi C, Golfieri R, Paccapelo A, Pagotto U, Pasquali R (2014) Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2(5):396–405. https://doi.org/10.1016/S2213-8587(13)70211-0
doi: 10.1016/S2213-8587(13)70211-0
pubmed: 24795253
Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E, Kharlip J, American Association of Clinical Endocrinologists; American Association of Endocrine Surgeons (2009) The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 15(1):1–20. https://doi.org/10.4158/EP.15.S1.1
doi: 10.4158/EP.15.S1.1
pubmed: 19632967
Kapoor A, Morris T, Rebello R (2011) Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 5(4):241–247. https://doi.org/10.5489/cuaj.11135
doi: 10.5489/cuaj.11135
pubmed: 21801680
pmcid: 3147036
Lee JM, Kim MK, Ko SH, Koh JM, Kim BY, Kim SW, Kim SK, Kim HJ, Ryu OH, Park J, Lim JS, Kim SY, Shong YK, Yoo SJ, Korean Endocrine Society, Committee for Clinical Practice Guideline (2017) Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul) 32(2):200–218. https://doi.org/10.3803/EnM.2017.32.2.200
doi: 10.3803/EnM.2017.32.2.200
pubmed: 28685511
Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, Reimondo G, Pia A, Toscano V, Zini M, Borretta G, Papini E, Garofalo P, Allolio B, Dupas B, Mantero F, Tabarin A, Italian Association of Clinical Endocrinologists (2011) AME position statement on adrenal incidentaloma. Eur J Endocrinol 164(6):851–870. https://doi.org/10.1530/EJE-10-1147
doi: 10.1530/EJE-10-1147
pubmed: 21471169
NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens State Sci Statements. 2002 19: 1–25. PMID: 14768652
Tabarin A, Bardet S, Bertherat J, Dupas B, Chabre O, Hamoir E, Laurent F, Tenenbaum F, Cazalda M, Lefebvre H, Valli N, Rohmer V, French Society of Endocrinology Consensus (2008) Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann Endocrinol (Paris) 69(6):487–500. https://doi.org/10.1016/j.ando.2008.09.003
doi: 10.1016/j.ando.2008.09.003
pubmed: 19022420
Bednarczuk T, Bolanowski M, Sworczak K, Górnicka B, Cieszanowski A, Otto M, Ambroziak U, Pachucki J, Kubicka E, Babińska A, Koperski Ł, Januszewicz A, Prejbisz A, Górska M, Jarząb B, Hubalewska-Dydejczyk A, Glinicki P, Ruchała M, Kasperlik-Załuska A (2016) Adrenal incidentaloma in adults-management recommendations by the Polish Society of Endocrinology. Endokrynol Pol 67(2):234–258. https://doi.org/10.5603/EP.a2016.0039
doi: 10.5603/EP.a2016.0039
pubmed: 27082051
Chomsky-Higgins K, Seib C, Rochefort H, Gosnell J, Shen WT, Kahn JG, Duh QY, Suh I (2018) Less is more: cost-effectiveness analysis of surveillance strategies for small, nonfunctional, radiographically benign adrenal incidentalomas. Surgery 163(1):197–204. https://doi.org/10.1016/j.surg.2017.07.030
doi: 10.1016/j.surg.2017.07.030
pubmed: 29129360
Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, Murad MH, O’Reilly MW, Arlt W, Bancos I (2019) Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med 171(2):107–116. https://doi.org/10.7326/M18-3630
doi: 10.7326/M18-3630
pubmed: 31234202
American Diabetes Association Professional Practice Committee (2022) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care 45(1):S17–S38. https://doi.org/10.2337/dc22-S002
doi: 10.2337/dc22-S002
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455
doi: 10.1093/eurheartj/ehz455
pubmed: 31504418
Davenport E, Lang Ping Nam P, Wilson M, Reid A, Aspinall S (2014) Adrenal incidentalomas: management in British district general hospitals. Postgrad Med J 90(1065):365–369. https://doi.org/10.1136/postgradmedj-2013-132386
doi: 10.1136/postgradmedj-2013-132386
pubmed: 24686243
Vassilatou E, Vryonidou A, Michalopoulou S, Manolis J, Caratzas J, Phenekos C, Tzavara I (2009) Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf) 70(5):674–679. https://doi.org/10.1111/j.1365-2265.2008.03492.x
doi: 10.1111/j.1365-2265.2008.03492.x
pubmed: 19067718
Bülow B, Jansson S, Juhlin C, Steen L, Thorén M, Wahrenberg H, Valdemarsson S, Wängberg B, Ahrén B (2006) Adrenal incidentaloma—follow-up results from a swedish prospective study. Eur J Endocrinol 154(3):419–423. https://doi.org/10.1530/eje.1.02110
doi: 10.1530/eje.1.02110
pubmed: 16498055
Yener S, Ertilav S, Secil M, Demir T, Akinci B, Kebapcilar L, Comlekci A, Bayraktar F, Yesil S (2010) Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest 33(1):32–36. https://doi.org/10.1007/BF03346546
doi: 10.1007/BF03346546
pubmed: 19542759
Ceccato F, Tizianel I, Voltan G, Maggetto G, MeranteBoschin I, Quaia E, Crimì F, Scaroni C (2021) Attenuation value in adrenal incidentalomas: a longitudinal study. Front Endocrinol (Lausanne) 12:794197. https://doi.org/10.3389/fendo.2021.794197
doi: 10.3389/fendo.2021.794197
pubmed: 34925247
Tatár J (1938) Glaukom bei Morbus Cushing. Graefes Arch Ophthal 139:793–800
doi: 10.1007/BF02084835
Schwartz B, McCarty G, Rosner B (1987) Increased plasma free cortisol in ocular hypertension and open angle glaucoma. Arch Ophthalmol 105(8):1060–1065. https://doi.org/10.1001/archopht.1987.01060080062029
doi: 10.1001/archopht.1987.01060080062029
pubmed: 2888454
Haas JS, Nootens RH (1974) Glaucoma secondary to benign adrenal adenoma. Am J Ophthalmol 78(3):497–500. https://doi.org/10.1016/0002-9394(74)90238-4
doi: 10.1016/0002-9394(74)90238-4
pubmed: 4413577
Jain A, Wordinger RJ, Yorio T, Clark AF (2012) Spliceosome protein (SRp) regulation of glucocorticoid receptor isoforms and glucocorticoid response in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 53(2):857–866. https://doi.org/10.1167/iovs.11-8497
doi: 10.1167/iovs.11-8497
pubmed: 22205602
pmcid: 3317424
Munkboel CH, Baake MLK, Styrishave B (2018) Atorvastatin decreases steroid production in H295R cells and in major endocrine tissues of male rats. Arch Toxicol 92(5):1703–1715. https://doi.org/10.1007/s00204-018-2187-y
doi: 10.1007/s00204-018-2187-y
pubmed: 29574565
London E, Tatsi C, Soldin SJ, Wassif CA, Backlund P, Ng D, Biesecker LG, Stratakis CA (2020) Acute statin administration reduces levels of steroid hormone precursors. Horm Metab Res 52(10):742–746. https://doi.org/10.1055/a-1099-9556
doi: 10.1055/a-1099-9556
pubmed: 32040961
pmcid: 7495505
Reincke M, Fassnacht M, Väth S, Mora P, Allolio B (1996) Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22(4):757–761. https://doi.org/10.1080/07435809609043773
doi: 10.1080/07435809609043773
pubmed: 8969938
Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi A, Della Casa S (2011) The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf) 74(3):300–5. https://doi.org/10.1111/j.1365-2265.2010.03928.x
doi: 10.1111/j.1365-2265.2010.03928.x
pubmed: 21070314
Fernández-Real JM, Engel WR, Simó R, Salinas I, Webb SM (1998) Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Clin Endocrinol (Oxf) 49(1):53–61. https://doi.org/10.1046/j.1365-2265.1998.00437.x
doi: 10.1046/j.1365-2265.1998.00437.x
pubmed: 9797847
Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M (2019) Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism 92:121–135. https://doi.org/10.1016/j.metabol.2018.11.001
doi: 10.1016/j.metabol.2018.11.001
pubmed: 30445141
Di Dalmazi G, Vicennati V, Pizzi C, Mosconi C, Tucci L, Balacchi C, Cosentino ER, Paolisso P, Fanelli F, Gambineri A, Pelusi C, Repaci A, Garelli S, Galiè N, Borghi C, Golfieri R, Pagotto U (2020) Prevalence and incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: a long-term study. J Clin Endocrinol Metab 105(8):dgaa270. https://doi.org/10.1210/clinem/dgaa270
doi: 10.1210/clinem/dgaa270
pubmed: 32413902
Sokmen G, Sahin M, Tuzun D, Sokmen A, Bolat H, Oguz A, Doganer A, Nacar H, Gul K (2018) Assessment of subclinical cardiac alterations and atrial electromechanical delay by tissue doppler echocardiography in patients with nonfunctioning adrenal incidentaloma. Arq Bras Cardiol 111(5):656–663. https://doi.org/10.5935/abc.20180188
doi: 10.5935/abc.20180188
pubmed: 30328944
pmcid: 6248257
Park MH, Park SI, Kim JH, Yu J, Lee EH, Seo SR, Jo SH (2019) The acute effects of hydrocortison on cardiac electrocardiography, action potentials, intracellular calcium, and contraction: the role of protein kinase C. Mol Cell Endocrinol 494:110488. https://doi.org/10.1016/j.mce.2019.110488
doi: 10.1016/j.mce.2019.110488
pubmed: 31207272
Sbardella E, Minnetti M, D’Aluisio D, Rizza L, Di Giorgio MR, Vinci F, Pofi R, Giannetta E, Venneri MA, Vestri A, Morelli S, Lenzi A, Isidori AM (2018) Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol 178(5):501–511. https://doi.org/10.1530/EJE-17-0986
doi: 10.1530/EJE-17-0986
pubmed: 29510982
Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, Lang K, Tsagarakis S, Macech M, Riester A, Deutschbein T, Pupovac ID, Kienitz T, Prete A, Papathomas TG, Gilligan LC, Bancos C, Reimondo G, Haissaguerre M, Marina L, Grytaas MA, Sajwani A, Langton K, Ivison HE, Shackleton CHL, Erickson D, Asia M, Palimeri S, Kondracka A, Spyroglou A, Ronchi CL, Simunov B, Delivanis DA, Sutcliffe RP, Tsirou I, Bednarczuk T, Reincke M, Burger-Stritt S, Feelders RA, Canu L, Haak HR, Eisenhofer G, Dennedy MC, Ueland GA, Ivovic M, Tabarin A, Terzolo M, Quinkler M, Kastelan D, Fassnacht M, Beuschlein F, Ambroziak U, Vassiliadi DA, O’Reilly MW, Young WF Jr, Biehl M, Deeks JJ, Arlt W, ENSATEURINE-ACT Investigators (2020) Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol 8(9):773–781. https://doi.org/10.1016/S2213-8587(20)30218
doi: 10.1016/S2213-8587(20)30218
pubmed: 32711725
pmcid: 7447976